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Additional files
Additional file 1: Supplementary Figure 1 (S1) . Drug screening and identification of Mortaparib as a p53-activating drug. Schemetic representation of screening assay (A).
Double immunostaining of mortalin and p53 in MCF7 and U2OS showed that Mortaparib treatment caused shift in mortalin staining pattern from perinuclear to pancytoplasmic, and increase in nuclear p53 (Scale bar=5µM) (B). Cell viability assay showing different level of cytotoxicity of Mortaparib to various cancer cell lines (C). Dose-dependent cytotoxicity was detected in HeLa, ME180, SKG-II, SKG-IIIb, OVK18, SKOV3; the latter two of these showed remarkably stronger effect as compared to other cancer cells and the normal fibroblasts (MRC5) (D). Long-term viability assay (colonogenicity) showed decrease in the number of colonies in Mortaparib-treated HeLa cells (E).
Chemical structure of Mortaparib and its molecular weight (F). The quantitative data represents mean ± SD obtained from at least three independent experiments; p-values were calculated using Student's t-test. *< 0.05, **< 0.01, and ***< 0.001 represent significant, very significant, and very very significant, respectively. Mortaparib did not show significant binding to Mortalin. Figure 3 (S3 
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